WEED.TO - Canopy Growth Corporation

Toronto - Toronto Delayed Price. Currency in CAD
39.49
+0.20 (+0.51%)
At close: 4:16PM EST
Stock chart is not supported by your current browser
Previous Close39.29
Open39.99
Bid39.35 x 0
Ask39.49 x 0
Day's Range38.13 - 40.36
52 Week Range20.36 - 76.68
Volume2,274,237
Avg. Volume4,519,014
Market Cap13.534B
Beta (3Y Monthly)2.42
PE Ratio (TTM)N/A
EPS (TTM)-2.39
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est66.83
  • Top Marijuana Stocks to Buy in 2019
    Motley Fool25 minutes ago

    Top Marijuana Stocks to Buy in 2019

    2019 could be the biggest year ever for the global cannabis industry. And these five marijuana stocks may be the winners.

  • Citron Boosts Shorted Pot Stock: Industry Dynamics Have Just Changed
    Investor's Business Daily5 hours ago

    Citron Boosts Shorted Pot Stock: Industry Dynamics Have Just Changed

    One of Wall Street's most notorious short-sellers — and a onetime skeptic of marijuana stocks — is giving Canadian cannabis producer Aphria a big assist.

  • Marijuana Stocks In 2019: Time To Separate 'Winners From The Sinners'
    Investor's Business Daily5 hours ago

    Marijuana Stocks In 2019: Time To Separate 'Winners From The Sinners'

    Will marijuana stocks implode in 2019? Will the farm bill be a major catalyst? Here's a 2019 outlook for what to expect from the marijuana industry.

  • Market Realist6 hours ago

    Why Aphria Surged 9% Today

    Aphria (APHA)(APHQF) surged almost 9% today as of 2:10 PM ET. The stock gained momentum as a result of a press release announcing that the company will introduce its oral strip to the German market. This product is to work in conjunction with a previously announced agreement with Rapid Dose for the exclusive right to manufacture, license, and distribute Rapid Dose’s QuickStrip oral strip.The details

  • GlobeNewswire7 hours ago

    Canopy Rivers Portfolio Company TerrAscend Gains Traction in New Jersey Medical Cannabis Market

    OTCQX: TRSSF), NETA NJ LLC (“NETA”), has been selected by the State of New Jersey Department of Health to apply for final approval to operate a vertically integrated Alternative Treatment Center (ATC), which would permit it to cultivate, process and sell medical cannabis in the state. The State of New Jersey received a total of 146 applications to cultivate, process and sell medical cannabis.

  • Market Realist7 hours ago

    Tilray Announced a Deal with Novartis, Rose 11%

    Earlier on December 18, Tilray (TLRY) announced a supply deal with Novartis—one of the largest global drug makers. Tilray stock rose nearly 11% following the announcement. Novartis stock was trading ~1.3% lower on in the European market.

  • What Else to Look For in the Cannabis Industry Next Year
    Market Realist10 hours ago

    What Else to Look For in the Cannabis Industry Next Year

    The cannabis industry will likely continue to move beyond early-stage products such as dried cannabis flower to more value-added products with a variety of uses and formats of consumption. Companies (HMMJ) such as Canopy Growth (WEED), Cronos Group (CRON), Organigram (OGRMF), and CannTrust (CNTTF) may move to differentiate their products including extracts, gels, oils, and other formats to carve out their niche in the highly competitive market. The next development that we’ll be closely watching in 2019 is consolidation and synergies. We’ll be interested in seeing how the cannabis market continues to consolidate with more acquisitions. We’ll also be watching the evolution of partnerships and ventures between cannabis companies with the goal of taking advantage of synergies.

  • Top Ten Developments to Watch in the Cannabis Sector in 2019
    Market Realist11 hours ago

    Top Ten Developments to Watch in the Cannabis Sector in 2019

    2019 will likely be the busiest year yet for the cannabis sector (MJ), and it will also be the year when the cannabis sector sees its first full year of realized potential after legalization in Canada. Will the cannabis industry validate the premises behind its existence such as huge market demand, reduced crime, and access to better quality of products for adult use? In the quarterly earnings, we’ll see how companies performed year-over-year with regards to their revenue growth and profitability.

  • A Look Back at Key Developments in the Cannabis Sector in 2018
    Market Realist13 hours ago

    A Look Back at Key Developments in the Cannabis Sector in 2018

    The cannabis industry has seen highs and lows in 2018. Before we do that, let’s recap what happened to the four developments listed in our previous series from June, Top Four Developments We’re Watching in the Cannabis Sector. In the second half of 2018, the cannabis sector remained busy getting cannabis products from production to customers.

  • Tilray Makes a Bold Prediction on Cannabis Legalization in the US
    Market Realistyesterday

    Tilray Makes a Bold Prediction on Cannabis Legalization in the US

    In the earlier part of this series, we looked at how Canopy Growth (WEED) is testing hemp-based CBD products to lower anxiety in dogs. While talking about the different uses of hemp-based CBD in its Q2 2019 earnings call, Canopy Growth said that it could develop anti-inflammatory products such as sports drinks for the US market. Canopy Growth is preparing for the US market, but Tilray (TLRY) is not far behind.

  • Why Legalizing Hemp in US Opens Doors for Innovation
    Market Realistyesterday

    Why Legalizing Hemp in US Opens Doors for Innovation

    Canopy Growth is expected to spend nearly 5.3 million Canadian dollars in research and development in 2019, as seen in the above chart. Canopy Growth stated that it is developing CBD-based drugs to lower anxiety in dogs. The company believes that this development could then lead it to develop an anxiety-reducing drug for geriatric patients. For Canopy Growth, it is more important to find end uses of CBD products from hemp than to pursue the farming and extraction business.

  • Canadian Cannabis Companies Set Sights on US Hemp Market
    Market Realistyesterday

    Canadian Cannabis Companies Set Sights on US Hemp Market

    The latest developments in the US, particularly the ones surrounding the Farm Bill, have been encouraging to the cannabis industry in the US. One of the most important changes that cannabis companies have been waiting for is legislation on hemp farming. On December 12, the Senate passed the Farm Bill, which will have a term of five years. The bill makes hemp a legal agricultural commodity, which would allow cannabis companies a legal foray into the US cannabis market.

  • ACCESSWIREyesterday

    4 Marijuana Stocks To Watch Before Christmas

    Not only has it caused a stir with US pot stocks but Canadian marijuana stocks are also seeing more activity this week. With marijuana stocks in focus, here are 4 pot stocks to watch this month. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced earlier this month that as a part of its growth strategy to cover the major verticals associated with primary care, it has signed a binding Letter of Intent to acquire a Vancouver, British Columbia based pharmacy.

  • Cannabis Stocks: Last Week’s Negative Performance
    Market Realist2 days ago

    Cannabis Stocks: Last Week’s Negative Performance

    In the week ending December 14, the cannabis sector was broadly in the negative territory. The Horizons Marijuana Life Sciences ETF (HMMJ) fell 6.1% week-over-week. The ETFMG Alternative Harvest ETF (MJ) also ended in the negative territory with a 5.7% decline, while the Emerging Marijuana Growers Index ETF (HMJR) declined 2.5% during the same period.

  • 5 Things That Really Matter When Investing in Marijuana Stocks
    Motley Fool2 days ago

    5 Things That Really Matter When Investing in Marijuana Stocks

    Hint: Peak production potential isn't one of them.

  • Hemp! Hemp! Hooray! Congress Passes the Farm Bill
    Motley Fool2 days ago

    Hemp! Hemp! Hooray! Congress Passes the Farm Bill

    There's now a clear path to legalizing hemp and hemp-derived CBD in the U.S. Here's what that really means.

  • This Tiny Marijuana Stock Could Be Better Prepared for the Coming Supply Glut Than Canopy Growth and Tilray
    Motley Fool2 days ago

    This Tiny Marijuana Stock Could Be Better Prepared for the Coming Supply Glut Than Canopy Growth and Tilray

    When the going gets tough in the Canadian marijuana market, there could be a surprising winner.

  • Better Buy: Canopy Growth vs. Cronos Group
    Motley Fool3 days ago

    Better Buy: Canopy Growth vs. Cronos Group

    Big deals for both of these marijuana producers have excited investors. But which stock will be the bigger winner down the road?

  • Hemp Is on the Brink of U.S. Legalization: Is Canopy Growth Positioned to Profit?
    Motley Fool3 days ago

    Hemp Is on the Brink of U.S. Legalization: Is Canopy Growth Positioned to Profit?

    Congress passed the Farm Bill this week, which President Trump is expected to sign, opening the floodgates for rapid growth in the hemp-derived CBD product market in the U.S.

  • This Small-Cap Cannabis Stock Is Up Big in a Down Market. Here's Why.
    Motley Fool4 days ago

    This Small-Cap Cannabis Stock Is Up Big in a Down Market. Here's Why.

    Medical Marijuana's stock has started to heat up. Here's why.

  • ACCESSWIRE4 days ago

    Marijuana Stocks Rally After Farm Bill Boost

    CORAL GABLES, FL / ACCESSWIRE / December 14, 2018 / For marijuana stocks and those that trade them, the most recent announcements surrounding the US Farm Bill this week have become somewhat of a catalyst for the industry. Not only has it caused a stir with US pot stocks but Canadian marijuana stocks are also seeing more activity this week. With marijuana stocks in focus, here are 4 pot stocks to watch this month.

  • Market Realist4 days ago

    Tilray Invests in ROSE LifeScience

    On December 14, Tilray (TLRY) announced that it’s investing in ROSE LifeScience—a cannabis producer in Quebec. The agreement between Tilray’s subsidiary High Park Farms and ROSE LifeScience entails an exclusive sale, distribution, supply, and marketing agreement. Tilray will spend 7.5 million Canadian dollars, which accounts for 12% in capital for ROSE LifeScience.